Selective detection of Cathepsin E proteolytic activity.

TitleSelective detection of Cathepsin E proteolytic activity.
Publication TypeJournal Article
Year of Publication2010
AuthorsAbd-Elgaliel WR, Tung C-H
JournalBiochim Biophys Acta
Volume1800
Issue9
Pagination1002-8
Date Published2010 Sep
ISSN0006-3002
KeywordsCatalysis, Cathepsin D, Cathepsin E, Drug Design, Fluorescence, Humans, Oligopeptides, Protease Inhibitors, Substrate Specificity
Abstract

BACKGROUND: Aspartic proteases Cathepsin (Cath) E and D are two different proteases, but they share many common characteristics, including molecular weight, catalytic mechanism, substrate preferences, proteolytic conditions and inhibition susceptibility. To define the biological roles of these proteases, it is necessary to elucidate their substrate specificity. In the present study, we report a new peptide-substrate that is only sensitive to Cath E but not Cath D.

METHODS: Substrate e, Mca-Ala-Gly-Phe-Ser-Leu-Pro-Ala-Lys(Dnp)-DArg-CONH₂, designed in such a way that due to the close proximity of a Mca-donor and a Dnp-acceptor, near complete intramolecular quenching effect was achieved in its intact state. After the proteolytic cleavage of the hydrophobic motif of peptide substrate, both Mca and Dnp would be further apart, resulting in bright fluorescence.

RESULTS: Substrate e showed a 265 fold difference in the net fluorescence signals between Cath E and D. This Cath E selectivity was established by having -Leu**Pro- residues at the scissile peptide bond. The confined cleavage site of substrate e was confirmed by LC-MS. The catalytic efficiency (K(cat)/K(M)) of Cath E for substrate e was 16.7 μM⁻¹S⁻¹. No measurable catalytic efficiency was observed using Cath D and no detectable fluorescent changes when incubated with Cath S and Cath B.

CONCLUSIONS: This study demonstrated the promise of using the developed fluorogenic substrate e as a selective probe for Cath E proteolytic activity measurement.

GENERAL SIGNIFICANCE: This study forms the foundation of Cath E specific inhibitor development in further studies.

DOI10.1016/j.bbagen.2010.06.005
Alternate JournalBiochim Biophys Acta
PubMed ID20600629
PubMed Central IDPMC2914798
Grant ListR01 CA135312 / CA / NCI NIH HHS / United States
CA 135312 / CA / NCI NIH HHS / United States
R21 CA114149 / CA / NCI NIH HHS / United States
R33 CA114149 / CA / NCI NIH HHS / United States
R01 CA135312-03 / CA / NCI NIH HHS / United States
Related Institute: 
Molecular Imaging Innovations Institute (MI3)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065